The FDA has opened up the use of Johnson & Johnson’s miniaturized heart pumps to certain pediatric patients, including those ...

The pumps, left-sided Impella heart pumps made by Johnson & Johnson MedTech’s Abiomed, have been linked to more than 100 serious injuries, including 49 deaths. The alert advises customers of new ...

Abiomed makes the bulk of its $1 billion-plus annual sales from its Impella range of heart pumps, which are billed as the smallest such devices available in the world and have enjoyed double-digit ...

Johnson & Johnson today announced the FDA has expanded its approval of Impella heart pumps to treat specific pediatric ...

Impella ECP is a technology of Abiomed, part of Johnson & Johnson MedTech, and the global leader in heart recovery. The pivotal investigational device exemption (IDE) study, which enrolled 256 ...

Impella 5.5 and Impella CP enable heart recovery as part of the world's smallest heart pump platform. Johnson & Johnson MedTech (Abiomed, Inc.) has partnered with the Advanced Cardiac Therapies ...

A spokesperson for Johnson & Johnson - which acquired Abiomed in 2022 - told Reuters: "This notification is not a device removal and Impella heart pumps remain on the market and available for ...

Impella 5.5 and Impella CP are the first left ... Johnson & Johnson MedTech (Abiomed, Inc.) has partnered with the Advanced Cardiac Therapies Improving Outcomes Network (ACTION) 1 to provide ...